Evidence map›Paper›PMID 34315564›Full record

ArticleOncology research2022

uPAR Controls Vasculogenic Mimicry Ability Expressed by Drug-Resistant Melanoma Cells.

Elena Andreucci, Anna Laurenzana, Silvia Peppicelli, Alessio Biagioni, Francesca Margheri, Jessica Ruzzolini, Francesca Bianchini, Gabriella Fibbi, Mario Del Rosso, Chiara Nediani and 4 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Elena AndreucciDepartment of Experimental and Clinical Biomedical Sciences Mario Serio, University of FlorenceFlorenceItaly.
Anna LaurenzanaDepartment of Experimental and Clinical Biomedical Sciences Mario Serio, University of FlorenceFlorenceItaly.
Silvia PeppicelliDepartment of Experimental and Clinical Biomedical Sciences Mario Serio, University of FlorenceFlorenceItaly.
Alessio BiagioniDepartment of Experimental and Clinical Biomedical Sciences Mario Serio, University of FlorenceFlorenceItaly.
Francesca MargheriDepartment of Experimental and Clinical Biomedical Sciences Mario Serio, University of FlorenceFlorenceItaly.
Jessica RuzzoliniDepartment of Experimental and Clinical Biomedical Sciences Mario Serio, University of FlorenceFlorenceItaly.
Francesca BianchiniDepartment of Experimental and Clinical Biomedical Sciences Mario Serio, University of FlorenceFlorenceItaly.
Gabriella FibbiDepartment of Experimental and Clinical Biomedical Sciences Mario Serio, University of FlorenceFlorenceItaly.
Mario Del RossoDepartment of Experimental and Clinical Biomedical Sciences Mario Serio, University of FlorenceFlorenceItaly.
Chiara NedianiDepartment of Experimental and Clinical Biomedical Sciences Mario Serio, University of FlorenceFlorenceItaly.
Simona SerratLaboratory of Nanotecnology, IRCCS Istituto Tumori Giovanni Paolo II,BariItaly.
Livia FucciPathology Department, IRCCS Istituto Tumori Giovanni Paolo II,BariItaly.
Michele GuidaRare Tumors and Melnaoma Unit, IRCCS Istituto Tumori Giovanni Paolo II,BariItaly.
Lido CaloriniDepartment of Experimental and Clinical Biomedical Sciences Mario Serio, University of FlorenceFlorenceItaly.
University of Florence · ITIstituto Tumori Bari · ITIstituti di Ricovero e Cura a Carattere Scientifico · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Malignant melanoma is a highly aggressive skin cancer characterized by an elevated grade of tumor cell plasticity. Such plasticity allows adaptation of melanoma cells to different hostile conditions and guarantees tumor survival and disease progression, including aggressive features such as drug resistance. Indeed, almost 50% of melanoma rapidly develop resistance to the BRAF

Indexed as

MelanomaPharmaceutical PreparationsCell Line, TumorDrug Resistance, NeoplasmHumansReceptors, Urokinase Plasminogen ActivatorVemurafenibPharmaceutical PreparationsReceptors, Urokinase Plasminogen ActivatorVemurafenib

Identifiers

PMID34315564
PMCPMC8790129
OpenAlexW3185726546

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.